Form 4: Entera Bio CFO Secures Substantial Equity Grant, Aligning Interests with Shareholders

Entera Bio Ltd.'s Chief Financial Officer, Dana Yaacov-Garbeli, received a significant grant of restricted stock units and stock options, approved by shareholders on July 16, 2025, in lieu of her 2024 cash bonus.

Summary

• Dana Yaacov-Garbeli, Chief Financial Officer of Entera Bio Ltd. (ENTX), was granted 26,316 stock-settled restricted stock units (RSUs) and 130,000 stock options.
• The RSUs were awarded in lieu of her 2024 annual cash bonus and are set to vest ratably on a quarterly basis over a one-year period, commencing April 28, 2025.
• The stock options carry an exercise price of $2.28 and will vest over a three-year period, also starting April 28, 2025, with one-third vesting on the first anniversary and the remainder vesting ratably quarterly over the subsequent two years.
• Both the RSU and stock option grants were initially approved by the Board of Directors on April 28, 2025, and subsequently received shareholder approval on July 16, 2025.
• Following these transactions, the CFO beneficially owns 113,047 ordinary shares indirectly through A2Z Counseling Ltd. and directly holds 130,000 stock options.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a key executive (CFO) is generally positive as it aligns management's interests with shareholders and incentivizes long-term performance. The use of equity in lieu of a cash bonus can also be seen as a positive for cash management. There are no negative implications from this specific filing.

Positives

• The grant of restricted stock units and stock options directly aligns the Chief Financial Officer's long-term financial interests with those of the company's shareholders, fostering a shared commitment to value creation.
• Awarding equity in lieu of a 2024 annual cash bonus demonstrates a strategic approach to cash conservation while still providing competitive compensation to a key executive.
• Shareholder approval of the grants on July 16, 2025, underscores transparency and strong corporate governance, indicating alignment between management and the company's ownership base regarding executive incentives.

Negatives

• No explicit negatives are stated in this Form 4 filing, which primarily reports an executive compensation grant.

Risks

• No specific risks are detailed in this Form 4 filing, which focuses on insider ownership changes related to executive compensation.

Future Outlook

The vesting schedules for the restricted stock units (one year from April 28, 2025) and stock options (three years from April 28, 2025) establish a forward-looking compensation structure designed to incentivize the Chief Financial Officer's long-term performance and retention.

Management Comments

• The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
• The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Industry Context

Executive compensation, particularly through equity grants, is a common practice across industries to align management incentives with shareholder value. The specific structure, including RSUs in lieu of a cash bonus and multi-year option vesting, reflects a standard approach to long-term incentive plans in the biotechnology or pharmaceutical sector, where long development cycles often necessitate strategies for long-term retention of key personnel.

Comparison to Industry Standards

• The grant of equity (RSUs and stock options) as a significant component of executive compensation is a standard practice in the biotechnology and pharmaceutical industries, similar to companies like Moderna, BioNTech, or Regeneron, which frequently use equity to incentivize long-term value creation given the lengthy R&D cycles.
• Awarding RSUs in lieu of a cash bonus, as seen here for the 2024 annual bonus, is a common strategy for cash conservation, especially for growth-stage or R&D-intensive companies, aligning with practices observed in smaller biotech firms.
• The vesting schedule of one year for RSUs and three years for options is typical for executive incentive plans, designed to retain key personnel and encourage sustained performance, comparable to structures at companies like Sarepta Therapeutics or Alnylam Pharmaceuticals.

Corporate Governance

Related Party Transactions

• The reporting person has a 33.33% interest and effective control over voting and disposition of shares held by A2Z Counseling Ltd., which indirectly owns 113,047 ordinary shares of Entera Bio Ltd.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's interests with shareholders, potentially leading to better long-term performance and value creation. Shareholder approval of the grants indicates transparency and alignment.
• Employees: The compensation structure for a key executive might set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• Continued vesting of 26,316 restricted stock units quarterly over one year from April 28, 2025.
• Continued vesting of 130,000 stock options over three years from April 28, 2025, with one-third vesting on the first anniversary and the remainder quarterly over the subsequent two years.

Key Dates

Recommendation

Keywords

Entera Bio, ENTX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, CFO, Shareholder Approval, Equity Grant